Categories: News

NYSE Content Advisory: Pre-Market update + Bad Boy Mowers Pinstripe Bowl Rings Opening Bell

NEW YORK, Dec. 26, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Ashley Mastronardi delivers the pre-market update on December 26th

- Advertisement -
  • After the Christmas break, stocks opened mixed, following Wednesday’s shortened session where the S&P 500 hit a record high, rising 0.3% to 6,932.
  • NYSE-listed Nike surged over 4.5%, while Citigroup climbed nearly 2% during Wednesday’s trading.
  • Players from Penn State and Clemson will ring today’s Opening Bell. NYSE Live will feature interviews with coaches Dabo Swinney and Terry Smith, plus Pinstripe Bowl Executive Director Mark Holtzman.

Opening Bell
Pinstripe Bowl participants Clemson & Penn State celebrate their upcoming matchup

- Advertisement -

Closing Bell
The Sled celebrates delivering Holiday Gift Wishes to thousands of NYC’s public-school children

- Advertisement -

Click here to download the NYSE TV App

- Advertisement -

Video – https://mma.prnewswire.com/media/2852003/NYSE_Market_Update_December_26.mp4
Logo – https://mma.prnewswire.com/media/2581322/5696150/New_York_Stock_Exchange_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update–bad-boy-mowers-pinstripe-bowl-rings-opening-bell-302649647.html

- Advertisement -

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

2 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

2 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

2 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

2 hours ago